The company follows pharmaceutical industry standards and regulations in order to manufacture medical grade products from the cannabis plant, intended for human use.
This includes up- and downstream processing, comprising of the cultivation of botanical raw materials as well as the extraction and purification of compounds from the various strains of the cannabis plant. All raw materials are treated as active pharmaceutical ingredients (APIs) and levels of herbicides, pesticides, fungi, endotoxins, mycotoxins, heavy metals, bacteria and solvents are held below the threshold set by American Herbal Pharmacopeia.
Cultivation will be performed according to WHO guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants and Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (ICH Q7). Pharmaceutical Quality Management System guidelines (ICH Q10) provide the basis for extraction, purification and consequent drug manufacturing. This will ensure the development of a drug complying with current good manufacturing guidelines, facilitating the entry into clinical trials and eventually registration as a therapeutic which is recognised by regulatory bodies world wide.
UTT BioPharma is focusing on the development of
UTT BioPharma possesses and is connected to a wealth of expertise in the areas of particle extraction and fractionation, chromatography and analytical chemistry. The company is determined to revolutionize the medicinal cannabis industry, which is expected to boom exponentially in the next decade.